Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylaxis Against Thromboembolic Disease Following Orthopaedic Surgeries on Extremities
Brief Summary: The purpose of this research is to find a better way to prevent the post operative development of clots in the deep veins of the legs (also called Deep Vein Thrombosis or DVT). DVT causes redness, swelling, and pain in the involved leg(s). Long-term complications may include permanent swelling and pain of the leg(s), and even skin ulcers around the ankle. If clots form in a leg after surgery, and break off, they can move to the lungs and block the pulmonary artery (also called Pulmonary Emboli or PE). With PE there can be chest pain, chest tightness, shortness of breath, coughing up blood, heart failure, and occasionally death.

Doctors have studied ways to reduce these complications. These studies led to the development of drugs which interfere with your body's clotting processes. However, it is still unclear which drug and which drug schedule is best. This study will evaluate two of the standard FDA approved drugs using different dosing schedules.


Options:
A: Intervention Type: DRUG; Name: SR34006; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: (LMW)heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Warfarin VKA; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acenocoumarol VKA; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux: | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fondaparinux:; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 3
C: Arm Label: Idrabiotaparinux; Type: EXPERIMENTAL; Interventions: Drug: Idrabiotaparinux sodium, Drug: Placebo (for warfarin), Drug: Avidin | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Placebo (for idrabiotaparinux), Drug: Placebo (for avidin) | Intervention Type: DRUG; Name: Idrabiotaparinux sodium; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Placebo (for idrabiotaparinux); Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Placebo (for warfarin); Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Avidin; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Placebo (for avidin); Assigned to Arm(s): Warfarin
D: Arm Label: SRI 15mg (15 mL/min ≤ CLCR < 20mL/min); Type: EXPERIMENTAL; Interventions: Drug: 15mg DU-176b | Arm Label: MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min); Type: EXPERIMENTAL; Interventions: Drug: 30mg DU-176b | Arm Label: Fondaparinux (20 mL/min ≤ CLCR < 30mL/min); Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Arm Label: SRI 15mg (20 mL/min ≤ CLCR < 30mL/min); Type: EXPERIMENTAL; Interventions: Drug: 15mg DU-176b | Intervention Type: DRUG; Name: 15mg DU-176b; Assigned to Arm(s): SRI 15mg (15 mL/min ≤ CLCR < 20mL/min), SRI 15mg (20 mL/min ≤ CLCR < 30mL/min) | Intervention Type: DRUG; Name: 30mg DU-176b; Assigned to Arm(s): MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min) | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux (20 mL/min ≤ CLCR < 30mL/min)

Answer: B